The New Health Report 2012

Rethinking the Risk Equation
in Biopharmaceutical Medicine

New Health Report

The New Health Report 2012: Download a copy of the New Health Report 2012

Learn More

Key Findings

Key Findings: Explore the key findings of this year's survey

View Key Findings

Stakeholders

Stakeholders: Examine results organized by stakeholder

View Stakeholder Data

Graphics Library

Graphics Library: Download ready-to-use graphics of New Health Report data

Learn More

The New Health Report 2012

Including the concept of value at risk into the conversations surrounding biopharmaceutical development and delivery

The New Health Report is Quintiles’ annual examination of biopharmaceutical stakeholders. The 2011 report looked to provide further understanding of stakeholder perceptions toward value in healthcare and medicine, and called upon open dialog and ongoing collaboration to foster an environment conducive to pharmacologic innovation. This year’s report aims to build upon that call for collaboration by exploring the element of value at risk as it relates to biopharmaceutical development and delivery.

Given the global macro-economic environment and many governments’ focus on balancing unfeasible budgets through austerity programs, the pressure for biopharmaceutical companies to demonstrate the value of their products for driving optimal improvement in public health has never been greater. As such, resulting policies—i.e., reimbursement and coverage decisions—will in large part be dictated by a framework that includes a formulaic process for determining a biopharmaceutical product’s value relative to its risks. Yet, while centralized paying bodies are a critical component for the ultimate commercial success of a new treatment, all other stakeholders within the healthcare ecosystem—biopharmaceutical companies, providers, patients and financial investors—also must determine the tradeoffs of how much of value is worth being put at risk, without the benefit of having either a standardized or centralized formula for doing so.


Key Findings

Much of the data analyzed in this report reveals the need for deeper knowledge of the inherent risks in healthcare and medicine. To address this, the biopharmaceutical industry must develop new approaches and do that as soon as possible. The results of this survey indicate that the industry can act now in several ways: collaborating early with payers on new compounds under development; striking pre-competitive alliances among industry competitors to enhance the innovative characteristics of new compounds; and developing risk-sharing agreements to enhance patient-population targeting.


Stakeholders

The New Health Report 2012 shows that healthcare stakeholders often disagree—between and within groups—on what risks matter the most. This study arises from a survey of 102 biopharmaceutical executives; 1009 patients living with a chronic disease in the United Kingdom or the United States; 72 National Health Service (NHS) executives in the United Kingdom; 75 managed care executives in the United States; and 100 investors with a focus on the life sciences sector.

News & Media

  • About The New Health Report

    The New Health Report 2012 was commissioned by Quintiles to further explore stakeholder sentiment in today's rapidly changing drug development universe. The report is based on surveys of biopharmaceutical executives, managed care executives in the U.S., National Health Service executives in the U.K., patients living with chronic disease in both the U.S. and the U.K., and investors who focus on the healthcare sectors. Each survey was conducted by Richard Day Research of Evanston, Illinois, U.S.A., a Market Probe company, on behalf of Quintiles. Richard Day Research was responsible for all survey design, data analysis and data reporting.

    Data for this survey were collected between January 8 and March 14, 2012. Screened and included in the sample were 102 biopharmaceutical executives at the director level or above, 75 managed care executives in the United States at the director level or above, 72 National Health Service executives (director or above) in the U.K., 509 U.S. and 500 U.K. adults ages 18+ diagnosed with a chronic health condition who are receiving treatment, and 100 investment professionals (vice president and above) employed in private equity firms, investment banks, or venture capital firms that focus on the healthcare/biopharma sector.

  • Media Contact

    Mari Mansfield, Media Relations, Quintiles
    +1 919 998 2639
    mari.mansfield@quintiles.com

  • Non-Media Contact

    Adam Istas, Corporate Communications, Quintiles
    +1 708 948 7070
    adam.istas@quintiles.com

  • About Quintiles

    Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. Our network of more than 25,000 professionals in 60 countries has an eye on the future while delivering results today with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies develop and commercialize products to improve and lengthen patients' lives while demonstrating value to stakeholders. Visit www.quintiles.com for more information and www.quintiles.com/news for additional company news.


Stay Connected